Group Leader - Early Discovery - Leiden (NL) at Charles River Nederland
Due to our continued growth we have an exciting opportunity for a talented, highly motivated individual at our state of the art drug discovery site in Leiden, the Netherlands.
The appointed Group Leader will be a key member of the Operational Management Team providing strong scientific, operational and strategic leadership to multiple project teams at the Leiden site of our Biology Department. You will have line management responsibility for the recruitment, development and retention of team members within the Biology team (6 to 20 (in)direct reports depending on your seniority).
You have significant experience as a line manager in an industrial drug discovery setting, ideally within a CRO environment, as the role includes responsibility for managing drug discovery project teams and individuals. Excellent interpersonal skills and the ability to motivate multiple teams are vital for this key role. You understand that our people are our most valuable asset and excel in helping them grow.
You will be familiar with all aspects of drug discovery (e.g. HTS, biomarker strategies and development of appropriate screening cascades), and have experience in complex in vitro biology, such as use of primary cells or stem cells in drug discovery. You are able to work across various therapeutic areas in order to apply these skills to ongoing and new projects. A flexible and dynamic approach towards achieving client-based objectives and meeting challenging deadlines is required, as is the ability to communicate confidently and concisely with clients via teleconferences, presentations and written reports.
In addition to leading your own project teams, you will be comfortable communicating across CRL sites in order to drive efficiencies and enhance best practice, and working with the global Business Development teams in order to establish client needs and provide guidance to appropriate methods of achieving their goals with regards to skills available across CRL.
Discovery from Charles River is industry-proven in the successful development of novel therapies, with over 320 patents and 74 preclinical drug candidates delivered to our sponsors in the past 17 years. Backed by more than 650 scientists, our comprehensive, integrated portfolio employs the latest technology and platforms to provide chemistry, biology, and pharmacology services that support clients from the earliest stages of hit identification all the way through to IND. Our client-focused, collaborative approach creates true partnerships that anticipate challenges, overcome obstacles, and move us forward together on the journey of getting new drugs to market.
About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and nonGLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.
With over 11,000 employees within 70 facilities in 18 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2016, revenue increased by 23.3% to $1.68 billion from $1.36 billion in 2015.
At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~70% of the drugs approved by the FDA in 2016.
For more information, please visit www.criver.com.